Historical syk News Stories
Stryker Surge: Analyst Targets $421 Amid Sell-Off!
Recent coverage of Stryker (SYK) accelerated this week as analysts lifted price targets toward $421 while insiders continued net selling. Operational recovery after a cyberattack and mixed valuation signals keep risk and opportunity balanced for investors.
Stryker SYK Restores Ops; Tariff & Cyber Risks Now
Stryker (SYK) has restored operations after a mid‑March cyberattack and reaffirmed its 2026 outlook even as tariff pressures and an ongoing import probe create near‑term headwinds. Strong margin expansion, aggressive EPS guidance for 2026, and elevated institutional buying support the stock, while insider sales and regulatory uncertainty merit attention.
Stryker (SYK) Rebounds After Cyberattack, Dividend
Stryker confirmed full operational recovery after a March cyberattack, reaffirmed 2026 organic growth guidance, and announced a $0.88 quarterly dividend. Strong institutional ownership and elevated trading volume accompanied the recovery, while an insider share sale drew attention. These developments sharpen near-term investor focus on execution and supply-chain restoration.
Stryker (SYK) Cyberattack Disrupts Operations News
A March cyberattack forced Stryker offline, wiping devices and interrupting ordering systems, prompting a near-term stock decline. Strong Q4 2025 results, product momentum (Mako robotics, new devices) and an upgraded UBS price target temper the outlook but operational risks and insider selling remain notable headwinds.
Stryker's AAOS Rollout & Insider Buy Shift SYK Now
Stryker (SYK) unveiled new orthopedic robotics and implants at AAOS 2026 while a meaningful insider purchase signaled management confidence. Shares dipped modestly as investors weighed commercialization timing and revenue impact.
Stryker Sharpens Robotics Focus; Spine Asset Sale!
Stryker (SYK) doubled down on robotics after Q4 beats, selling spine manufacturing assets to VB Spine while guiding solid 2026 growth. Mako adoption, margin expansion, analyst upgrades and a short stock rally balanced by insider sales define the near-term story.
Stryker Q4 Beat Fuels Mako RPS and T2 Launch Gains
Stryker (SYK) posted a strong Q4 2025 beat and issued upbeat 2026 guidance while rolling out new Mako RPS robotic tools and the T2 Alpha Humerus system. Short-term headwinds — vascular inventory adjustments, interest expense, and EU regulatory timing — temper near-term momentum, but product launches and solid fundamentals support investor confidence.
Stryker Q4 Beat, Guidance Steady — Stock Lags Now!
Stryker reported a solid Q4 beat with double-digit organic growth and raised 2026 guidance, yet SYK shares slipped on elevated volume this week. This article breaks down the results, the market reaction, and the near-term implications for investors.